SEARCH

Click on the blue print button to print or save the monograph as a PDF. Search for another drug by typing into the box above.

Vial $4.99

Cefepime

Editor: Updated Class:

ADMINISTRATION ROUTES:

Intravenous

ICU INDICATIONS:

  1. Empiric treatment of neutropenic sepsis, febrile neutropenia, and some hospital acquired infections
  2. Treatment of infections caused by susceptible organisms.

PRESENTATION AND ADMINISTRATION:

INTRAVENOUS:

Compatible with the following fluids:

Sodium Chloride 0.9% or Glucose 5%

Store the undiluted product below 25˚C and protect from light.

2 gram powder for injection vials

Reconstitution:

Reconstitute each vial with 10 mL of compatible fluid. Reconstituted solutions are stable for up to 24 hours refrigerated. Solution may darken on storage without affecting potency.

Central or peripheral line may be used

Intravenous Infusion (preferred method):

Dilute to final volume of 50 mL of a suitable diluent and administer over 30 minutes.
Diluted solutions can be stored for up to 24 hours either at room temperature or refrigerated.

Intravenous Injection (alternative method):

Inject the reconstituted solution slowly over 3-5 minutes.

Reserve this method of administration where clinically necessary, e.g. in fluid-restricted patients.

There have been reports of increased risk of serious adverse effects with rapid administration of cefepime, especially in critically ill patients.

DOSAGE:

INTRAVENOUS:

2 g three times a day

DOSAGE IN RENAL FAILURE AND RENAL REPLACEMENT THERAPY:

Dose in Renal Impairment

GFR (mL/min) DOSE
> 50 dose as in normal renal function
30-50 2 g twice a day
11-29 2 g once a day
< 10 1g once a day

Dose in Renal Replacement Therapy

MODALITY DOSE
CAPD 1 - 2 g every 48 hours
HD 1 g once a day. On dialysis days, administer dose after dialysis session.
CVVHDF 2 g twice a day

DOSAGE IN HEPATIC IMPAIRMENT:

No dose adjustment necessary

DOSAGE IN PAEDIATRICS:

50 mg/kg intravenously every 8 hours

Maximum 2 g per dose

CLINICAL PHARMACOLOGY:

  • Onset of Action: Within 30 minutes
  • Duration of Action: 2-4 hours
  • Elimination: 8 hours in normal renal function

Cefepime is a broad-spectrum fourth-generation cephalosporin antibiotic used to treat moderate-to-severe bacterial infections.

Onset of action is rapid following intravenous administration. Elimination is predominantly renal with an elimination half-life of 2 - 2.5 hours in patients with normal renal function

When organisms are susceptible, cefepime is active against the following organisms in vitro and in clinical infections:

Aerobes, Gram-positive

  • Staphylococcus aureus (methicillin-susceptible strains only)
  • Streptococcus pneumoniae
  • Streptococcus pyogenes

Aerobes, Gram-negative

  • Enterobacter
  • Escherichia coli
  • Klebsiella pneumoniae
  • Proteus mirabilis
  • Pseudomonas aeruginosa
  • AmpC beta-lactamase-producing Enterobacterales

Anaerobes, Gram-positive No reliable activity

Most strains of enterococci e.g. Enterococcus faecalis, and methicillin-resistant staphylococci are resistant to cefepime. Cefepime is inactive against many strains of Stenotrophomonas (formerly Xanthomonas maltophilia and Pseudomonas maltophilia). Cefepime is inactive against most strains of Clostridium difficile. Cefepime does not provide MRSA coverage. Cefepime does not provide dependable anaerobic coverage.

Cefepime is generally not recommended for invasive infections or complicated urinary tract infections due to ESBL-producing Enterobacterales, even where susceptibility is reported.

CONTRAINDICATIONS:

  1. Hypersensitivity to cephalosporins

WARNINGS:

Anaphylaxis

Cephalosporins are a common cause of anaphylactic reactions and cross reactivity with penicillins may occur

Neurotoxicity

Cefepime-associated neurotoxicity may cause encephalopathy, reduced consciousness, agitation, myoclonus, seizures or non-convulsive status epilepticus. Risk increases with renal impairment, excessive drug exposure, older age and underlying neurological disease. Neurotoxicity may occur despite apparently appropriate renal dose adjustment. Suspect cefepime neurotoxicity in patients with otherwise unexplained deterioration in neurological function. Discontinue cefepime when toxicity is suspected and consider EEG assessment. Haemodialysis may accelerate removal in severe cases.

Pseudomembranous colitis

Pseudomembranous colitis has been reported with nearly all antibacterial agents, including cefepime, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea subsequent to the administration of antibacterial agents

PRECAUTIONS:

General:

Prescribing cefepime in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Positive direct Coombs' tests have been reported during treatment with the cephalosporin antibiotics. It should be recognised that a positive Coombs' test may be due to the drug.

Laboratory Tests:

No tests additional to usual ICU tests are required

Drug/Laboratory Test Interactions :

A false positive reaction for glucose in the urine may occur with Benedict's solution, Fehling's solution or with Clinitest tablets, but not with enzyme-based tests such as Clinistix.

Positive direct and indirect antiglobulin (Coombs) tests have occurred; these may also occur in neonates whose mothers received cephalosporins before delivery.

IMPORTANT DRUG INTERACTIONS IN ICU:

Concurrent use of probenecid may decrease renal tubular secretion of cephalosporins resulting in increased and more prolonged cephalosporin drug levels. Concurrent administration of aminoglycosides and potent diuretics may increase cefepime exposure due to renal dysfunction.

ADVERSE REACTIONS:

General:

Anaphylaxis, itching, drug fever, Stevens-Johnson syndrome

Neurological:

Headache, agitation, altered mental status, confusion, coma, encephalopathy, neurotoxicity, myoclonus, seizures, tremor, slurred speech

Haematological: Neutropaenia, leukopaenia, thrombocytopaenia, thrombocythaemia, eosinophilia, false positive Coomb's test

Dermatological:

Skin rash, vulvar pruritus, injection site pain, phlebitis

Gastrointestinal:

Diarrhoea, oral candidiasis (oral thrush), vomiting, nausea, stomach cramps, anorexia and pseudomembranous colitis

Hepatic:

Transient rises in ALT, AST, and alkaline phosphatase levels has been observed. As with other cephalosporins, reports of hepatitis and cholestatic jaundice have been received

Metabolic and Endocrine:

Hypophosphatemia, hyperphosphatemia, increased serum calcium, increased serum potassium

Cephalosporin-Class Adverse Reactions: In addition to the adverse reactions listed above, the following reactions and altered laboratory tests have been reported for cephalosporin-class antibiotics: fever, abdominal pain, superinfection, renal dysfunction, toxic nephropathy, haemorrhage, false positive test for urinary glucose, elevated bilirubin, elevated LDH, and pancytopaenia.